Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

Novogene Acquires China Rights to Urine-based DNA Collection Device

publication date: Jul 12, 2017
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Novogene, a Beijing genomics services company, partnered with San Diego's Trovagene to validate and use Trovagene's NextCollect™ in China. NextCollect is a proprietary urine collection and nucleic acid preservation device that stabilizes up to 200 ml of a urine sample for two weeks at room temperature. According to Trovagene, the device increases the quality and quantity of DNA that can be isolated from urine. Presently, NextCollect is a research-only device, but Novogene intends to develop clinical applications. More details....

Stock Symbol: (NSDQ: TROV)

Share this with colleagues:  


This article is available for purchase - please click here for details.


Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login